open access

Vol 7, No 3 (2018)
REVIEW ARTICLES
Published online: 2018-05-21
Get Citation

Human insulin – is there still a place for it in everyday practice?

Katarzyna Nabrdalik, Hanna Kwiendacz, Janusz Gumprecht
DOI: 10.5603/DK.2018.0014
·
Clinical Diabetology 2018;7(3):171-174.

open access

Vol 7, No 3 (2018)
REVIEW ARTICLES
Published online: 2018-05-21

Abstract

Type 2 diabetes is a progressive disease where in case of unsuccessful behavioral modifications and metformin
monotherapy treatment needs to be intensified by adding some other oral agents and/or GLP-1 agonists and/ /or basal insulin. After some years of treatment with increasing defect of beta cells, there is a necessity to start or intensify insulin therapy with prandial insulin, premixed insulin, basal-bolus regimen or multiple injections of insulin. Patient’s treatment should be individualized but there are no direct recommendations which type of insulin to choose — human or analogue one. This article summarizes clinical situations in which one could consider using human insulin. When selecting a suitable insulin, the type of dietary habits, especially eating snacks, the presence of gastroparesis and economic issues should be taken into account. It turnes out that for patients with type 2 diabetes both human and analogue insulins are equally safe and efficient in terms of risk of severe hypoglycaemia. Undoubtedly, analogue insulin has uncontestable advantages, but in some clinical cases human insulin seems to be a better option.

Abstract

Type 2 diabetes is a progressive disease where in case of unsuccessful behavioral modifications and metformin
monotherapy treatment needs to be intensified by adding some other oral agents and/or GLP-1 agonists and/ /or basal insulin. After some years of treatment with increasing defect of beta cells, there is a necessity to start or intensify insulin therapy with prandial insulin, premixed insulin, basal-bolus regimen or multiple injections of insulin. Patient’s treatment should be individualized but there are no direct recommendations which type of insulin to choose — human or analogue one. This article summarizes clinical situations in which one could consider using human insulin. When selecting a suitable insulin, the type of dietary habits, especially eating snacks, the presence of gastroparesis and economic issues should be taken into account. It turnes out that for patients with type 2 diabetes both human and analogue insulins are equally safe and efficient in terms of risk of severe hypoglycaemia. Undoubtedly, analogue insulin has uncontestable advantages, but in some clinical cases human insulin seems to be a better option.

Get Citation

Keywords

diabetes mellitus; human insulin; analogue insulin

About this article
Title

Human insulin – is there still a place for it in everyday practice?

Journal

Clinical Diabetology

Issue

Vol 7, No 3 (2018)

Pages

171-174

Published online

2018-05-21

DOI

10.5603/DK.2018.0014

Bibliographic record

Clinical Diabetology 2018;7(3):171-174.

Keywords

diabetes mellitus
human insulin
analogue insulin

Authors

Katarzyna Nabrdalik
Hanna Kwiendacz
Janusz Gumprecht

References (19)
  1. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation. http://www.diabetesatlas.org (2017).
  2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012; 55(6): 1577–1596.
  3. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21): 2005–2012.
  4. Levy P. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Postgrad Med. 2009; 121(3 Suppl 1): 7–12.
  5. Danne T, Heinemann L, Bolinder J. New Insulins, Biosimilars, and Insulin Therapy. Diabetes Technol Ther 2018; 20: 55-70 DOI: 10 1089/dia. ; 2016: 2505.
  6. Polskie Towarzystwo Diabetologiczne. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2018. Clinical Diabetology. 2018; 4(suppl A).
  7. Standards of Medical Care in Diabetes—2018 Introduction. Diabetes Care. 2018; 41: 1–2.
  8. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1): 140–149.
  9. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007(2): CD005613.
  10. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006(2): CD003287.
  11. dziennikustaw.gov.pl/du/2018/281/D2018000028101.pdf.
  12. Davidson M. Insulin Analogs—Is There a Compelling Case to Use Them? No!: Table 1. Diabetes Care. 2014; 37(6): 1771–1774.
  13. Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab. 2007; 9(5): 630–639.
  14. Kalra S, Balhara YPS, Sahay BK, et al. Why is premixed insulin the preferred insulin? Novel answers to a decade-old question. J Assoc Physicians India. 2013; 61(1 Suppl): 9–11.
  15. Nabrdalik K, Kwiendacz H, Sawczyn T, et al. Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study. International Journal of Endocrinology. 2018; 2018: 1–7.
  16. Alipour Z, Khatib F, Tabib SM, et al. Assessment of the Prevalence of Diabetic Gastroparesis and Validation of Gastric Emptying Scintigraphy for Diagnosis. Mol Imaging Radionucl Ther. 2017; 26(1): 17–23.
  17. Sieradzki J. Gastrointestinal neuropathy and different insulins. s.l. : Diab Clin. 2010; 11: 35–38.
  18. Umpierrez GE, Jones S, Smiley D, et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care. 2009; 32(7): 1164–1169.
  19. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause? Diabetes Care. 2001; 24(1): 174.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl